{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/tennis-elbow/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"a4cdd522-1fab-5734-88a9-37368f9d9703","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field d23014f3-c5cb-47ea-9642-b6b200588a0c --><h2>Changes</h2><!-- end field d23014f3-c5cb-47ea-9642-b6b200588a0c -->","summary":null,"htmlStringContent":"<!-- begin item 9745eea6-c254-4a82-b231-7b70fd081bd5 --><!-- begin field 8c643564-08a2-491a-a3c0-cd6b85f9a580 --><p><strong>November 2020</strong> — reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. There have been minor structural changes, and a recommendation not to use corticosteroids routinely for treating tennis elbow has been added to this topic.</p><!-- end field 8c643564-08a2-491a-a3c0-cd6b85f9a580 --><!-- end item 9745eea6-c254-4a82-b231-7b70fd081bd5 -->","topic":{"id":"38b48145-bad1-5b47-bd4b-977116102717","topicId":"0e648ed3-5f54-45b7-b4b1-62002677af9d","topicName":"Tennis elbow","slug":"tennis-elbow","lastRevised":"Last revised in November 2020","chapters":[{"id":"1fa5d5e6-9a93-5203-9b7e-976d03c1ae61","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c2f532d9-fea1-5fca-8c15-38e650af4a91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"23579cc6-24d0-5e7f-aba1-ad1c0481b40c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a4cdd522-1fab-5734-88a9-37368f9d9703","slug":"changes","fullItemName":"Changes"},{"id":"92684a0e-bce5-58fa-9b9c-770fa672ed97","slug":"update","fullItemName":"Update"}]},{"id":"08ba25dd-fa4a-5a2a-803d-cf84b189adc1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df92f795-8a37-5177-9c44-aaa9d98306df","slug":"goals","fullItemName":"Goals"},{"id":"e1f2e3df-1739-5a99-bbe2-ddbecaa9a249","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"14e4fbf7-5930-57dd-ab46-7cf4f338b145","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58d2a644-f6f1-5018-a32c-935b272fde58","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e49c6155-bc3f-5d6b-aa4a-3a11a20e292e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2804b807-874f-5ce6-b37b-9eb11e68b165","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c0d695b-efbc-5b19-9c2f-a44dd0ea6e6d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c07505ef-35a4-59b0-af5f-039d0ce035d7","slug":"definition","fullItemName":"Definition"},{"id":"de88ddb5-c603-5dd9-9653-1cbc307e7b28","slug":"causes","fullItemName":"Causes"},{"id":"7ede2fe1-ba9b-5b3d-9e69-a368e8e5ec66","slug":"prevalence","fullItemName":"Prevalence"},{"id":"283925f5-cd2c-5275-8abc-80ff31a6a779","slug":"prognosis","fullItemName":"Prognosis"},{"id":"186295a5-5d7f-5032-bca8-4b28396d13b1","slug":"complications","fullItemName":"Complications"}]},{"id":"edaf3310-36a3-5579-80be-7e6f2bfd07d3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3a8f9339-5633-5a11-80e1-390bab3aa80b","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e865c96a-8c63-5601-84d2-d3c0a0cf6979","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e245c67a-34b7-5625-b9eb-3c5f95044fe8","fullItemName":"Management","slug":"management","subChapters":[{"id":"377fa2ac-038d-5026-a35a-145cff6dd082","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"707bfd3c-0b4c-53b9-a881-add5dfda5bfb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"441736ee-1ce8-5d8e-a636-7187fd454767","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d441c13c-ffd3-52b6-9520-18ee52df05ab","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b0da926f-bfb5-5e84-9010-34465bc4fe83","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7a058e09-bdf5-5b31-824e-8ce766146dcf","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"85a374b8-15bd-5bb4-90bb-304bd337105d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"98b4806c-1489-5b69-bd1c-da6dfca6b964","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7668b04f-e3ac-5b0e-a998-96e9605dc665","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"23579cc6-24d0-5e7f-aba1-ad1c0481b40c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e5fc764a-591d-54c0-a036-14e2fe636823","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d4d4fd5e-0b22-4725-a59a-5536ac572945 --><h3>Previous changes</h3><!-- end field d4d4fd5e-0b22-4725-a59a-5536ac572945 -->","summary":null,"htmlStringContent":"<!-- begin item 4b982bba-07e8-4f95-ae95-21ff000aff2d --><!-- begin field 80036971-e1de-4984-8383-614afbb6613b --><p><strong>July 2020</strong> — minor update. Change made to patient sources of information to reflect that Arthritis Research UK has been rebranded as Versus Arthritis, and the link to Versus Arthritis patient leaflet updated.</p><p><strong>November 2017</strong> — reviewed. A literature search was conducted in November 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone minor restructuring. A node on <em>Differential diagnosis</em> has been created in the <em>Diagnosis</em> section. The recommendations on the diagnosis and management of tennis elbow have been amended in line with current evidence.</p><p><strong>April 2015 </strong>— minor update. A link to the CKS topic on <em>Analgesia - mild-to-moderate pain</em> has been added.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— revised. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No changes to clinical recommendations have been made.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>September 2010 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that topical ketoprofen is associated with a risk of photosensitivity reactions. Issued in September 2010.</p><p><strong>June 2010 </strong>— minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Issued in July 2010.</p><p><strong>June 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised prescribers of the risk of photosensitivity reactions for people using topical ketoprofen. Issued in June 2009.</p><p><strong>January 2009 </strong>— minor update. Addition to text in the <em>Background information</em> section and to the text on advice in the section on <em>Treatment</em>. Issued in February 2009.</p><p><strong>September to December 2008 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 80036971-e1de-4984-8383-614afbb6613b --><!-- end item 4b982bba-07e8-4f95-ae95-21ff000aff2d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}